NEW YORK, Feb. 10 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. , invites investors, the media and the general public to listen to a live audio webcast of its KRX-101 (sulodexide gelcap) Analyst Day Meeting at 4:30pm ET on Wednesday, February 15, 2006. Expert presentations focusing on diabetic nephropathy and reviewing the KRX-101 (sulodexide oral gelcap) clinical program will be made by Edmund J. Lewis, MD, head of the Collaborative Study Group and principal investigator of the Phase III and IV studies, as well as other leading clinical investigators from the KRX-101 clinical program.
The live webcast can be accessed via the homepage of Keryx's website at http://www.keryx.com, and will be archived and available for replay following the event. The meeting is expected to last approximately two hours.
ABOUT KERYX BIOPHARMACEUTICALS, INC.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is KRX-101 (sulodexide), a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. KRX-101 is in a pivotal Phase 3 and Phase 4 clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing clinical-stage oncology compounds, including KRX-0401, a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.
KERYX CONTACT: Ron Bentsur Vice President - Finance & Investor Relations Keryx Biopharmaceuticals, Inc. Tel: 212.531.5965 E-mail: ron@keryx.com
Keryx Biopharmaceuticals, Inc.CONTACT: Ron Bentsur, Vice President - Finance & Investor Relations, ofKeryx Biopharmaceuticals, Inc., +1-212.531.5965, ron@keryx.com
Web site: http://www.keryx.com/
